Allena Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Newton MA United States (2011)

Organization Overview

First Clinical Trial
2014
NCT02289755
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Allena Pharmaceuticals | Allena Pharmaceuticals Inc | Allena Pharmaceuticals, Inc | Allena Pharmaceuticals, Inc. | Allena Pharmceuticals

Active Ingredients

Drugs in Phase 3 Trials (2)

alln-177 (5 trials)

oxalate decarboxylase (1 trial)

Drugs in Phase 2 Trials (1)

alln-346 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calculi (Phase 2)

Hyperoxaluria (Phase 2)

Hyperoxaluria, Primary (Phase 2)

Hyperuricemia (Phase 2)

Kidney Calculi (Phase 2)

Neoplasm Metastasis (Phase 2)

Nephrolithiasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 3